Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease

Obesity, Morbid Clinical Trial

Official title:

Integrated Multi-omics and Machine Learning-driven Personalized Treatment of Obesity-associated Fatty Liver Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05554224
• Other study ID #: EOM study
• Secondary ID: EPIMET
• Status: Recruiting
• Start date: June 25, 2008
• Est. completion date: December 31, 2028

Study information

• Verified date: March 2024
• Source: Institut Investigacio Sanitaria Pere Virgili
• Contact: Jorge Joven, Professor
• Phone: +34977310300
• Email: jorge.joven[@]urv.cat
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors influencing inter-organ crosstalk. The main aim is to improve the interpretation of fatty liver disease associated with obesity and diabetes by developing predictive models built with algorithms from artificial intelligence. The challenge is to decipher the flow of information by exploring contributing factors, proximate causes of regulatory defects, and maladaptive responses that may promote therapeutic approaches.

Description:

The investigators study the most prevalent liver disease in the history of humankind, which is the leading cause of liver transplantation in its severe forms. It results from two silent pandemics with enormous health impacts: obesity and diabetes. Together or separately, they affect more than 30% of the world's population. The current term for the disease is MAFLD (metabolic (dysfunction)-associated fatty liver disease). This designation indicates that metabolic disorders related to obesity, diabetes, dyslipidemia, and hypertension are its primary cause. These disorders are related and lead to fat accumulation in the liver, the first step in a broad spectrum of chronic liver diseases. These diseases respond clinically in a very variable way and remain undiagnosed and untreated for a long time. There is no accepted pharmacological treatment, and lifestyle changes, although possibly effective, usually fail because they require particularly favorable conditions. Therefore, the identified problems that should be solve are:

(1) The diagnosis of MAFLD requires a liver biopsy, a costly and aggressive procedure. (2) Without examining the liver, clinicians can know little about the progression of the disease and the underlying causes. (3) The results in experimental models can be informative but difficult to translate to the clinic. Recent reports suggest the essential role of phospholipid biosynthesis and transport between the endoplasmic reticulum and mitochondria. (4) All of the above makes it difficult to obtain the necessary information to propose changes in clinical guidelines.

Considering these aspects, patients with morbid obesity can be an informative human model. Among other advantages, patients have surgical options that allow us to obtain portions of affected organs that facilitate specific diagnosis and that, because they require constant care, can be studied on an ongoing basis. The presented approach can improve patient care and essentially consists of identifying the most significant number of variables that can help. In particular, here are proposed the inclusion of variables that can already be obtained from recent advances in the laboratory, encompassed within the omics sciences (genomics, transcriptomics, proteomics, metabolomics, lipidomics, microbiomics). Each of these has its advantages and limitations. Predictive models can integrate these variables into clinical data to explore organ crosstalk.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1104
• Est. completion date: December 31, 2028
• Est. primary completion date: December 31, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Body mass index greater or equal to 40 kg/m^2.

• Body mass index between 35 and 40 kg/m^2 with high-risk comorbidities (diagnosis or treatment for hypertension, dyslipidemia, or type 2 diabetes mellitus).

• Positive psychiatric evaluation.

• Age greater or equal to 18 years old.

Exclusion Criteria:

• Legal or illegal drug consumption, including alcohol.

• Diagnosis of Hepatitis.

• Current cancer diagnosis or treatment.

• Clinical or analytical evidence of severe illness.

• Clinical or analytical evidence of chronic or acute inflammation.

• Clinical or analytical evidence of infectious diseases.

• Clinical or analytical evidence of terminal illness.

Related Conditions & MeSH terms

• Comorbidities and Coexisting Conditions
• Fatty Liver
• Liver Diseases
• NAFLD
• Obesity
• Obesity, Morbid

Intervention

Diagnostic Test:
• To propose diagnostic tests for liver diseases before surgical decisions.
Observational although patients are candidates for metabolic surgery.

Locations

Country	Name	City	State
Spain	Hospital Universitari Sant Joan	Reus	Tarragona

Sponsors (5)

Lead Sponsor	Collaborator
Institut Investigacio Sanitaria Pere Virgili	Hospital Universitari Sant Joan, Instituto de Salud Carlos III, La Caixa Foundation, University of Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight change	The effect of bariatric surgery on adiposity outcomes.	1 to 10 years
Primary	Type 2 diabetes mellitus incidence	The effect of bariatric surgery on metabolic outcomes.	1 to 10 years
Primary	Hypertension incidence	The effect of bariatric surgery on metabolic outcomes.	1 to 10 years
Primary	Chronic liver diseases incidence	The usefulness of imaging techniques on metabolic outcomes.	1 to 10 years
Primary	Dyslipidemia incidence	The effect of bariatric surgery on metabolic outcomes.	1 to 10 years